Erlotinib (Tarceva™, OSI-774; Pfizer, Inc.) is an orally-active, targeted inhibitor of the
epidermal growth factor receptor (EGFR/HER1), which is part of a key regulatory pathway in …

The objective of this systematic review and meta-analysis was to assess and contrast the
efficacy and safety of combining erlotinib and bevacizumab with erlotinib alone in the …

Opinion statement Gefitinib is a small molecule that specifically inhibits the tyrosine kinase
activity of the epidermal growth factor receptor (EGFR) type 1 by interfering with the …

Objective To compare the efficacy of the erlotinib versus gefitinib in the first-line treatment of
patients with advanced EGFR mutation-positive NSCLC. Methods Fifty patients with …

BACKGROUND. Erlotinib is an orally available, reversible inhibitor of epidermal growth
factor receptor (EGFR) with a proven survival advantage for patients with locally advanced …

Methods Previously treated patients with EGFR TKI–naive advanced NSCLC were randomly
assigned to receive oral erlotinib (150 mg daily) plus oral tivantinib (360 mg twice daily) or …

Purpose A multicenter randomized phase II trial to evaluate two treatment strategies in the
first-line management of advanced non–small-cell lung cancer (NSCLC) patients with a …

Erlotinib is a highly potent inhibitor of epidermal growth factor receptor tyrosine-kinase
activity that significantly prolongs overall survival in patients with non-small-cell lung cancer …

Lung cancer is the leading cause of cancer deaths worldwide. Targeting the epidermal
growth factor receptor (EGFR) has played a central role in advancing non-small-cell lung …

Background Erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) is an oral, epidermal
growth factor receptor tyrosine kinase inhibitor that has antitumor activity and good …